Outcome | ITDM | NITDM | p Value (adjusted*) |
(n=644) | (n=1919) | ||
% (n) | % (n) | ||
MACE | 12.6 (81) | 8.7 (167) | 0.019 |
Death-all | 6.7 (43) | 3.2 (61) | <0.001 |
Cardiac death | 4.5 (29) | 2.1 (41) | 0.004 |
MI | 1.7 (11) | 1.9 (36) | 0.622 |
Q wave | 0.2 (1) | 0.6 (11) | 0.299 |
Non-Q wave | 1.6 (10) | 1.3 (25) | 0.959 |
Emergent CABG | 0.0 (0) | 0.0 (0) | NA |
TLR | 6.5 (42) | 4.9 (94) | 0.221 |
CABG | 0.5 (3) | 0.8 (16) | 0.408 |
PTCA | 6.2 (40) | 4.4 (84) | 0.152 |
TVR | 7.0 (45) | 5.3 (102) | 0.227 |
Not target lesion | 0.5 (3) | 0.6 (12) | 0.601 |
TVF | 11.0 (71) | 8.0 (153) | 0.050 |
ARC definite ST | 1.2 (8) | 0.7 (14) | 0.305 |
0–30 days | 0.8 (5) | 0.5 (9) | 0.370 |
31–365 days | 0.6 (4) | 0.3 (5) | 0.295 |
ARC definite+ prob. ST | 2.2 (14) | 1.3 (25) | 0.158 |
0–30 days | 1.6 (10) | 1.0 (19) | 0.253 |
31–365 days | 0.8 (5) | 0.3 (6) | 0.195 |
↵* p Values were calculated using logistic regression adjusted for propensity scores. Propensity scores were calculated using the following baseline variables: age, sex, prior MI, prior percutaneous transluminal coronary angioplasty, prior coronary artery bypass graft surgery, acute MI (<72 h), hypertension, hypercholesterolemia, smoking, left anterior descending coronary artery (LAD) (vs non-LAD), B2C (vs AB1), lesion length (≥27 mm vs <27 mm), and reference vessel diameter (>3.5 mm vs ≤3.5 mm).
ARC, Academic Research Consortium; CABG, coronary artery bypass grafting; DM, diabetes mellitus; ITDM, insulin-treated diabetes mellitus; MACE, major adverse cardiac events; MI, myocardial infarction; NA, not applicable; NITDM, non-insulin-treated diabetes mellitus; PTCA, percutaneous transluminal coronary angioplasty; ST, stent thrombosis; TLR, target lesion revascularisation; TVR, target vessel revascularisation; TVF, target vessel failure.